ACRS vs ECL · rev $18.7M vs P/E 35, rev $4.01B
Aclaris Therapeutics Inc (ACRS) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Latest reported ACRS revenue for 2024-12-31 was $18.7M. Net income was -$132.1M. Revenue was down 40.1% from 2023-12-31 to 2024-12-31. ACRS currently screens at market cap $615.9M.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
ACRS currently screens at market cap $615.9M. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the ACRS and ECL stock pages for the full models.
Not investment advice.